Statement of Changes in Beneficial Ownership (4)
August 17 2022 - 5:25PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Kelderman Kim |
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp
[
TECH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
PRES. DIAGNOSTICS & GENOM |
|
(Last)
(First)
(Middle)
614 MCKINLEY PL N E |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/15/2022 |
|
(Street)
MINNEAPOLIS, MN 55413
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | | | | | | | | 3138 | D |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Restricted Stock Units | (1) | 8/15/2022 | | A | | 1746 | | (2) | (2) | Common Stock | 1746 | $0 | 1746 | D |
|
| Stock Options (Right to Buy) | $378.08 | 8/15/2022 | | A | | 5426 | | (2) | 8/15/2029 | Common Stock | 5426 | $0 | 5426 | D |
|
| Stock Options (Right to Buy) | $378.08 | 8/15/2022 | | A | | 7235 | | (3) | 8/15/2029 | Common Stock | 7235 | $0 | 7235 | D |
|
| Stock Options (Right to Buy) | $150.78 | | | | | | | (4) | 5/1/2025 | Common Stock | 7511 | | 7511 | D |
|
| Stock Options (Right to Buy) | $177.32 | | | | | | | (5) | 8/8/2025 | Common Stock | 12044 | | 12044 | D |
|
| Stock Options (Right to Buy) | $177.32 | | | | | | | (6) | 8/8/2025 | Common Stock | 9033 | | 9033 | D |
|
| Stock Options (Right to Buy) | $190.41 | | | | | | | (7) | 8/7/2026 | Common Stock | 11961 | | 11961 | D |
|
| Stock Options (Right to Buy) | $190.41 | | | | | | | (8) | 8/7/2026 | Common Stock | 15948 | | 15948 | D |
|
| Restricted Stock Units | (1) | | | | | | | (2) | (2) | Common Stock | 2015 | | 2015 | D |
|
| Stock Options (Right to Buy) | $267.87 | | | | | | | (2) | 8/5/2027 | Common Stock | 8991 | | 8991 | D |
|
| Stock Options (Right to Buy) | $267.87 | | | | | | | (9) | 8/5/2027 | Common Stock | 11988 | | 11988 | D |
|
| Stock Options (Right to Buy) | $267.87 | | | | | | | (10) | 8/5/2027 | Common Stock | 8325 | | 8325 | D |
|
| Stock Options (Right to Buy) | $267.87 | | | | | | | (11) | 8/5/2027 | Common Stock | 8325 | | 8325 | D |
|
| Restricted Stock Units | (1) | | | | | | | (12) | (12) | Common Stock | 1245 | | 1245 | D |
|
| Stock Options (Right to Buy) | $481.82 | | | | | | | (13) | 8/6/2028 | Common Stock | 6486 | | 6486 | D |
|
| Stock Options (Right to Buy) | $481.82 | | | | | | | (12) | 8/6/2028 | Common Stock | 4864 | | 4864 | D |
|
| Explanation of Responses: |
| (1) | Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. |
| (2) | Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (3) | Options to purchase 1,809 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 1,808 shares vest on 8/15/2025. |
| (4) | Options to purchase 2,500 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022. |
| (5) | Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022. |
| (6) | Fully exercisable. |
| (7) | On 8/7/2022, the Board of Directors certified vesting of 2,363 performance shares. |
| (8) | Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023. |
| (9) | Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024. |
| (10) | Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
| (11) | Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
| (12) | Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| (13) | Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Kelderman Kim
614 MCKINLEY PL N E
MINNEAPOLIS, MN 55413 |
|
| PRES. DIAGNOSTICS & GENOM |
|
Signatures
|
| /s/ Brenda S. Furlow, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed | | 8/17/2022 |
| **Signature of Reporting Person | Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024
